SG11202000098RA - Polymorphic forms of dasatinib - Google Patents
Polymorphic forms of dasatinibInfo
- Publication number
- SG11202000098RA SG11202000098RA SG11202000098RA SG11202000098RA SG11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA
- Authority
- SG
- Singapore
- Prior art keywords
- dasatinib
- international
- present
- butanediol
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741024067 | 2017-07-07 | ||
IN201741029965 | 2017-08-24 | ||
IN201841001249 | 2018-01-11 | ||
IN201841007613 | 2018-02-28 | ||
PCT/IB2018/055022 WO2019008555A1 (en) | 2017-07-07 | 2018-07-07 | POLYMORPHIC FORMS OF DASATINIB |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000098RA true SG11202000098RA (en) | 2020-02-27 |
Family
ID=64949779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000098RA SG11202000098RA (en) | 2017-07-07 | 2018-07-07 | Polymorphic forms of dasatinib |
Country Status (12)
Country | Link |
---|---|
US (1) | US11059813B2 (zh) |
EP (1) | EP3649126A4 (zh) |
JP (1) | JP2020526528A (zh) |
KR (1) | KR20200036867A (zh) |
CN (1) | CN111108104A (zh) |
AU (1) | AU2018297710A1 (zh) |
BR (1) | BR112020000302A2 (zh) |
CA (1) | CA3069107A1 (zh) |
MX (1) | MX2020000185A (zh) |
RU (1) | RU2020105723A (zh) |
SG (1) | SG11202000098RA (zh) |
WO (1) | WO2019008555A1 (zh) |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01010292A (es) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
EP1937270A1 (en) | 2005-09-21 | 2008-07-02 | Brystol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
EP2508523B2 (en) * | 2007-10-23 | 2019-04-17 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
WO2010062715A2 (en) | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
WO2010067374A2 (en) | 2008-12-08 | 2010-06-17 | Hetero Research Foundation | Polymorphs of dasatinib |
CN102040596A (zh) * | 2009-10-10 | 2011-05-04 | 上海希迪制药有限公司 | 达沙替尼多晶型物及其制备方法 |
CN102030745B (zh) | 2010-11-26 | 2012-05-09 | 江苏先声药物研究有限公司 | Dasatinib溶剂合物及其制备方法 |
CN102086195B (zh) * | 2011-01-28 | 2013-04-03 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
ES2637829T3 (es) | 2012-06-15 | 2017-10-17 | Basf Se | Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados |
CZ306598B6 (cs) * | 2012-12-06 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu |
WO2015049645A2 (en) * | 2013-10-04 | 2015-04-09 | Alembic Pharmaceuticals Limited | An improved process for the preparation of dasatinib |
EP3160963A1 (en) * | 2014-06-30 | 2017-05-03 | Basf Se | Multicomponent crystals of dasatinib with menthol or vanillin |
EP3186284B1 (en) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
WO2016178148A1 (en) * | 2015-05-05 | 2016-11-10 | Glenmark Pharmaceuticals Limited | Process for preparation of dapagliflozin |
US10301302B2 (en) * | 2015-06-29 | 2019-05-28 | Msn Laboratories Private Limited | Crystalline forms of N-(2-chloro-6-methy]phenvn-2-[F6-[4-(2-hvdroxvethvl)-L-piperazin-vil-2-methvil-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof |
US9845303B2 (en) * | 2015-10-19 | 2017-12-19 | Cadila Healthcare Limited | Process for the preparation of dapagliflozin |
WO2017098391A1 (en) | 2015-12-11 | 2017-06-15 | Shilpa Medicare Limited | Process for the preparation of dasatinib |
WO2017134617A1 (en) * | 2016-02-03 | 2017-08-10 | Dr. Reddy's Laboratories Limited | Process for the preparation of amorphous dasatinib |
US10464933B2 (en) * | 2016-02-03 | 2019-11-05 | Dr. Reddy's Laboratories Limited | Solid state forms of dasatinib and processes for their preparation |
-
2018
- 2018-07-07 US US16/628,746 patent/US11059813B2/en active Active
- 2018-07-07 EP EP18827395.7A patent/EP3649126A4/en not_active Withdrawn
- 2018-07-07 RU RU2020105723A patent/RU2020105723A/ru unknown
- 2018-07-07 WO PCT/IB2018/055022 patent/WO2019008555A1/en unknown
- 2018-07-07 CA CA3069107A patent/CA3069107A1/en not_active Abandoned
- 2018-07-07 JP JP2020500624A patent/JP2020526528A/ja active Pending
- 2018-07-07 MX MX2020000185A patent/MX2020000185A/es unknown
- 2018-07-07 BR BR112020000302-6A patent/BR112020000302A2/pt not_active Application Discontinuation
- 2018-07-07 KR KR1020207003800A patent/KR20200036867A/ko not_active Application Discontinuation
- 2018-07-07 SG SG11202000098RA patent/SG11202000098RA/en unknown
- 2018-07-07 CN CN201880058510.0A patent/CN111108104A/zh active Pending
- 2018-07-07 AU AU2018297710A patent/AU2018297710A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3649126A4 (en) | 2021-04-07 |
EP3649126A1 (en) | 2020-05-13 |
BR112020000302A2 (pt) | 2020-07-14 |
JP2020526528A (ja) | 2020-08-31 |
CN111108104A (zh) | 2020-05-05 |
US20200377495A1 (en) | 2020-12-03 |
MX2020000185A (es) | 2021-01-29 |
CA3069107A1 (en) | 2019-01-10 |
RU2020105723A (ru) | 2021-08-09 |
AU2018297710A2 (en) | 2020-03-05 |
AU2018297710A1 (en) | 2020-02-27 |
WO2019008555A1 (en) | 2019-01-10 |
KR20200036867A (ko) | 2020-04-07 |
US11059813B2 (en) | 2021-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201909541WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201900634VA (en) | Chimeric antigen receptor | |
SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201811015RA (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
SG11201407458XA (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
SG11201900609PA (en) | Method and system for providing buffer solutions | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201810975UA (en) | Method for stabilizing proteins | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11201901140QA (en) | Compounds and methods for reducing tau expression | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201906552WA (en) | TGF-ß DECOY RECEPTOR | |
SG11201807885PA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |